Healthcare / BiotechnologyASX
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-6.3M · quality 36.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-358.7%
↓Gross Margin
100.0%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-81.6%
FCF CAGR
—
FCF margin
-3791618.1%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $238.0 · net income $-10.6M · FCF $-9.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $238.00 | $238.00 | $1963.00 | $5959.00 | $38285.00 |
| Net Income | $-10.6M | $-10.6M | $-5.1M | $-7.8M | $-3.4M |
| EBITDA | $-13.2M | $-13.2M | $-8.4M | $-9.0M | $-3.4M |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 |
| Gross Margin | 100.0% | 100.0% | -298.9% | 100.0% | 11.1% |
| Operating Margin | -5537853.4% | -5537853.4% | -428057.7% | -151855.5% | -10266.9% |
| Net Margin | -4453302.1% | -4453302.1% | -258240.0% | -130759.2% | -8782.1% |
| Balance Sheet | |||||
| Current Ratio | 7.30 | 7.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.0M | $-9.0M | $-4.6M | $-6.3M | $-3.0M |
| Returns | |||||
| ROE | -358.7% | -358.7% | -42.6% | -196.7% | -235.1% |
| Valuation | |||||
| P/B | 4.21 | 4.21 | 5.60 | 9.27 | 34.13 |
| Growth & Yield | |||||
| Revenue Growth | -87.9% | -87.9% | -67.1% | -84.4% | — |
| EPS Growth | -82.1% | -82.1% | 42.9% | -104.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
-40.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.